Table 1.
Characteristics of the current study participants.
| Diagnosis | Gender | Age (years) | Education (years) | MMSE score | Amyloid∗ (11C PiB-PET) | Glucose∗ (FDG-PET) | Family history of dementia (n) | ApoE 𝜀4 carriers (n) |
|---|---|---|---|---|---|---|---|---|
| Control n = 3 | W | 54.4 ± 3.8 | 15.3 ± 0.9 | 29.3 ± 0.5 | -0.7 ± 0.3 | 0.5 ± 0.2 | 2 | 0 |
| Predinical AD n = 3 | W | 58.4 ± 3.5 | 17.3 ± 1.2 | 29.0 ± 0.8 | 1.0 ± 11.3 | -0.9 ± 0.5 | 3 | 3 |
| Control n = 3 | M | 62.3 ± 2.5 | 15.3 ± 2.5 | 30.0 ± 0 | -0.6 ± 0.3 | 1.2 ± 0.5 | 2 | 1 |
| Predinical AD n = 3 | M | 63.8 ± 2.0 | 17.0 ± 0.8 | 29.7 ± 0.5 | 1.5 ± 1.6 | -1.1 ± 0.8 | 2 | 1 |
Data are presented as mean ± standard deviation. AD, Alzheimer’s disease; W, women; M, men; MMSE, Mini-Mental State Examination; 11C-PiB, 11C-labeled Pittsburgh compound B; PET, Positron emission tomography; FDG, 18F-fluorodeoxyglucose. ∗These measures are in arbitrary units (a.u.). The amyloid burden data (PiB-PET) were residualized for the effects of age and gender. The glucose metabolism data (FDG-PET) were residualized for the effects of age, gender, and global glucose metabolism.